key: cord-0815881-ce3m8zky
authors: Meshram, Hari Shankar; Kute, Vivek B.; Chauhan, Sanshriti
title: BK polyomavirus infection following COVID-19 infection in renal transplant recipients: a single-center experience
date: 2021-08-06
journal: Kidney Res Clin Pract
DOI: 10.23876/j.krcp.21.082
sha: 8c6984eac75ff55a665e765e211cb60f77767aaa
doc_id: 815881
cord_uid: ce3m8zky

nan

of the cohort in the physical, clinical, and psychological domains. Follow-up BKPyV testing was conducted at 1-month after discharge, followed by every 3 months thereafter. Testing also was performed in cases of increasing creatinine.

We identified 11 cases of BKPyV after infection in 167 total COVID-19 KTR cases. Table 1 shows the overall summary of the study. The median age of the cohort was 45 years (range, 29-56 years), with male predominance (90.9%). The majority of the cohort had comorbidities (72.7%), underwent live-related-donor transplantation (72.7%), and received thymoglobulin (81.8%) upon admission for COVID-19. The baseline median serum creatinine was 1.44 mg/dL (range, 1.3-1.9 mg/dL). COVID-19 severity was categorized as mild (9%), moderate (45%), and severe cases (46%) [4] . Acute kidney injury was reported in all cases, and acute respiratory distress syndrome developed in 18.2% of KTR patients, with one fatality during COVID-19 admission. Five cases (45.5%) received steroids during acute COVID-19 infection. At baseline, no cases showed BKPyV in the blood. Baseline polymerase chain reaction (PCR) urine testing of the cohort Table 1 . Characteristics of the cohort with BKPyV following SARS-CoV2 infection did not detect BKPyV in most cases (81.8%). Table 2 shows the laboratory parameters of the cohort. The median BKPyV blood and urine PCR results during acute COVID-19 infection were 2,509 copies/mL (range, 280-41,746 copies/mL) and 4,433,366 copies/mL (range, 7,602-198,681,183 copies/ mL), respectively. The follow-up period after BKPyV diagnosis was 7 months (range, 5-8 months). BKPyV was detected in the blood during the follow-up period in only one patient. The BKPyV PCR urine values of the cohort were less than those detected in 63.6% of the follow-up cases. No graft loss or graft dysfunction was reported in the cohort. No patient developed sensitization, urine microhematuria, or proteinuria during the follow-up period. Radiological resolution [5] of COVID-19 infection was defined as the absence of any chest radiographic abnormality potentially related to the infection; this type of resolution was seen in 91.6% of KTR cases and resolved after a median of 3 months of follow-up. No multisystemic sequelae were reported. One case was readmitted 1 week after discharge and died due to secondary fungal infection (aspergillosis) after 1 month.

Our report could simply indicate that the natural history and course of BKPyV happened to coincide with COVID-19 infection, and there might be no actual association between the two; however, reactivation of viruses like BKPyV is a high-risk factor for graft loss in transplant patients [6] . BK-PyV causes complex changes in immunity and weakens the immune response, which could potentially aggravate the immune/graft injury often present in COVID-19 infection [7] . Elevated levels of inflammatory cytokines in COVID-19 infection can lead to greater transcription of the BKPyV genome [8] . The use of thymoglobulin as an induction agent could have been a confounding factor for BKPyV, but the institutional protocol of using a low dosage of thymoglobulin (1.5 mg/kg) hinders this connection. Moreover, at our center, the incidence of BKPyV in COVID-19 patients was 6.6% (11 of 167 patients), which was higher than the rate reported in normal follow-up or in non-COVID-19 admissions (1.3%). While we were unable to show a definite association of BK-PyV with COVID-19 infection, the use of steroids to treat these patients and COVID-19 infection itself are both risk factors for an increase in number of BKPyV in KTRs. Therefore, we suggest screening for BKPyV in COVID-19 patients.

One limitation of this study was its small sample size. To date, this is the largest cohort of KTRs with BKPyV after Table 1 .

In summary, we report BKPyV following COVID-19 with no graft loss during the follow-up period. We suggest screening for BKPyV in all renal transplant patients with active COVID-19 infection (especially in patients with a history of BKPyV and in severe COVID-19 infection) as a safe option to avoid complications.

COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature

Resurgence of BK virus following Covid-19 in kidney transplant recipients

Identifying a kidney transplant recipient COVID phenotype to aid test utilization in the setting of limited testing availability-does one exist?

Directorate General of Health Services (EMR Division), Ministry of Health & Family Welfare, Government of India. Clinical management protocol: COVID-19. Version 3 [Internet]. New Delhi: Ministry of Health & Family Welfare, Government of India

Pneumonia recovery: discrepancies in perspectives of the radiologist, physician and patient

Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy

Sp1 sites in the noncoding control region of BK polyomavirus are key regulators of bidirectional viral early and late gene expression

All authors have no conflicts of interest to declare.

Conceptualization, Data curation, Formal analysis, Investigation: All authors Writing-original draft: All authors Writing-review & editing: All authors All authors read and approved the final manuscript.

Hari Shankar Meshram, https://orcid.org/0000-0001-9148-8168Vivek B. Kute, https://orcid.org/0000-0002-0002-2854 Sanshriti Chauhan, https://orcid.org/0000-0001-7385-5614